Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab +/- Umbralisib in Treatment-naive FL/MZL
NCT04508647Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab, umbralisib in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by University of Colorado Denver. Started Nov 2020; status: completed.
02
Drugs
ublituximabumbralisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04508647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508647.